Literature DB >> 9520177

Is the combination of hepatitis and indinavir potentially dangerous?

F J Jeurissen, M M Schneider, J C Borleffs.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520177

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

Review 1.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  A risk-benefit assessment of HIV protease inhibitors.

Authors:  G J Moyle; B G Gazzard
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

3.  Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.

Authors:  M Savès; F Raffi; P Clevenbergh; B Marchou; A Waldner-Combernoux; P Morlat; V Le Moing; C Rivière; G Chêne; C Leport
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

4.  Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS.

Authors:  A Bicart-Sée; P Massip; M D Linas; A Datry
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

5.  Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report.

Authors:  B Greenberg; A Berkman; R Thomas; D Hoos; R Finkelstein; J Astemborski; D Vlahov
Journal:  J Urban Health       Date:  1999-12       Impact factor: 3.671

Review 6.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.